2 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow MET Exon 14 Mutation: new trials by email Literature Review of MET Exon 14 Mutation trials Research Report on MET Exon 14 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated Tepotinib, Pemetrexed (Alimta), Vinorelbine - Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 133 | 2025-12-09 | 2025-12-17 |
| Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer Bozitinib - NSCLC, MET Exon 14 Mutation | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 34 | 2025-09-20 | 2025-09-04 |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2024-02-01 | 2023-10-10 |
Carcinoma, Non-Small-Cell Lung (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Docetaxel (1) · Gemcitabine (1) · Nivolumab (1) · Paclitaxel (1) · Pemetrexed (1) · Vinorelbine (1) · atezolizumab (1) · capmatinib (1) · dabrafenib (1) · pembrolizumab (1) · tepotinib (1) · trametinib (1)
Intergroupe Francophone de Cancerologie Thoracique (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sun Yat-sen University (1)
China (1) · France (1)